Meningococcal Polysaccharide Vaccine For Human

[Eligibles]Adults and children over two years of age.[Function and use]The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135.[Description]The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution.Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides.Subsidiary materials: All the components of subsidiary materials approved shall be listed.Vaccine diluent: Sterile, pyrogen-free PBS.[Specifications]0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135).[Feature]Fill a gap in our country for the first time by developing 4-valent vaccine .Improve traditional purification technology to eliminate nucleic acid and protein.Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards.1.Group ACYW135                             2.Group A+C